The Indian pharma industry is on its path of continuous growth and evolution. Today, India is the third largest global supplier of medicines by volume. It boasts more than 3,000 pharma organisations spread across close to 11,000 manufacturing units.
ProPharma Group is the leading global, independent, single-source provider of regulatory, clinical and compliance services serving pharma, biotech and medical devices companies. We have presence in six continents with more than 2,500 professionals providing the highest quality of services on a global scale supported by regional expertise. Our experts bring in a comprehensive portfolio of regulatory sciences, clinical research solutions, lifescience consulting, auditing, remediation services, R&D technology, pharmacovigilance and medical information services to help solve complex challenges in a dynamic regulatory environment. With our mission to improve the health and safety of patients, we are focussed on delivering the highest quality of services throughout the full product lifecycle.
ProPharma Group’s India business started with the acquisition of iSafety in 2021, one of the premier organisations in India providing pharmacovigilance services. In April 2022, ProPharma set up lifescience consulting in India to cater to the pharma and medical devices markets in India to offer their services.
Through lifescience consulting business in India, ProPharma Group offers a whole array of services including auditing, remediation, compliance to the EU and the US regulatory agencies, product and process lifecycle management, commissioning, qualification and validation, regulatory strategy, compliance, technology transfer, etc. We have a dedicated team of experts in India with extensive experience in global markets backed up by our global team of consultants.
James Kolbet, President, Life Science Consulting (Global), ProPharma Group, feels that Indian market has a lot of opportunities. He says, “As our scope of services and capacity grows, we are able to support our current and expanding client base with the critical services they need to achieve business goals. A vast number of global supply chains originate from India and we want to do our part to make them successful.”
Dr David Crome has spent over 20 years supporting many clients both in India and setting up their operations in Europe and the UK to be regulatorycompliant. Now, with the setting up of our lifesciences consulting division based in Mumbai under Amol Yelgaonkar, Director, Life Science Consulting, India, who has worked in the Indian pharma industry for last 25 years on global markets, and our worldwide network of consultants to call upon, we are able to support clients to achieve the development, expansion and export strategies on time. We will be available for helping organisations expand their business in semi- and highly regulated countries.
Dr David Crome, Managing Director, ProPharma Group, The UK and India says, “Our vision is to be with you throughout your business lifecycle, to support you through the inevitable challenges along the way, and be there to celebrate your achievements with you.”
Amol Yelgaonkar says, “ProPharma is here to serve pharmaceutical organisations who want to expand their businesses in the EU and the US and other regulated countries. With a collective experience and proven track record across the product lifecycle from R&D through to pharmacovigilance, we can cater to any of your requirements.”
About ProPharma Group
ProPharma Group is the industry leading global single sourced provider of scientific and technical services throughout the full product lifecycle, from development through to clinical and commercial production. We have 2500+ employees working with 1000+ clients in the pharmaceutical, biotechnology, medical device and diagnostics arenas. We work across six business divisions which are interlinked to support our clients throughout their product life cycle.
◆ R&D Technology
◆ Regulatory Sciences
◆ Clinical Research Solutions
◆ Life Science Consulting
◆ Pharmacovigilance
◆ Medical Information
ProPharma Group can support a wide range of clients covering the areas of KSM & API manufacturers, finished dosage forms, CROs, CMOs ATMP, gene therapy biotechnology companies, conventional small molecule pharmaceuticals, medical device, diagnostics, etc.
ProPharma Group is a global organization with local on the ground teams that are there to support you whenever you need them. With a strong work force of 2500+ experts globally in almost every pharma
market, we can cater to requirements right from research and development through to post commercial activities like Pharmacovigilance. ProPharma is a one-stop-solution for all your needs.
India is the largest global provider of generic drugs and ranks 3rd in terms of pharmaceutical production by volume and 13th by value. Their domestic pharmaceutical industry includes a network of 3,000 drug companies and 11,000 manufacturing units and they have the largest number of US FDA approved sites outside of the USA. Exports of pharmaceutical products were around US$25 billion last year with
around 50% going to North America and Europe. With the announcement of Pharma Vision 2020 and the setting up of the Hyderabad Pharma City and Genome Valley Park projects which are anticipated to attract US$8.4 billion of investment and generate over half a million jobs in the longer term, ProPharma Group sees this as a great opportunity to support these new businesses in getting their new facilities
commissioned and regulatory agency GMP inspection ready in
a timely manner.